ReviewApplied biochemistry and biotechnology2026
Current Advancements in Untargeted Metabolomics Analysis and Testing Driven by Machine Learning: Prospects for Artificial Intelligence in Patient-Centric Healthcare Transformation.
Review in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Beyond Feature Selection: Interpretable Machine Learning for Mechanistic Insights in Metabolomics.Biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolomics is a high-throughput methodology that measures various metabolites in biological fluids. An advantage of an untargeted approach for analyzing metabolomics, which involves an impartial examination of the metabolome, lies in its ability to identify crucial metabolites that contribute to, or serve as indicators of, human health and disease. This review discusses the significance of artificial intelligence and machine learning in advancing disease diagnosis and small molecule detection using untargeted metabolomics, providing an updated and integrative perspective on their recent impact in this field. The discussion focuses on how artificial intelligence and machine learning have contributed to the evolution of high-resolution mass spectrometry. This approach involves unbiased detection of endogenous and exogenous biochemical compounds and metabolites in biological tissue. It enables the characterization of exposures linked to disease outcomes by providing context for the applications of artificial intelligence and machine learning and exploring their roles in enhancing the precision and efficiency of disease exposure assessments. While several review articles address the application of artificial intelligence and machine learning in metabolomics, this article aims to highlight recent opportunities for leveraging these technologies specifically in untargeted metabolomics, covering improvements in data quality, methodological rigor, sensitivity in detection, and precise compound identification. The novelty holds transformative potential that artificial intelligence and machine learning bring to metabolomics, paving the way for more robust and insightful investigations.
Indexed as
Identifiers
41335389What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.